Condition: Systemic Mastocytosis With an Associated Hematologic Neoplasm · Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Systemic mastocytosis with an associated hematologic neoplasm (SM-AHN) is a challenging disease to treat. Targeted KIT inhibitors have been approved for this indication based on their ability to control the mastocytosis portion of the disease, but patients frequently experience progression of the concomitant myeloid malignancy (i.e. the AHN). Using a combination approach to treat both aspects of the disease has the potential to provide enhanced disease control; however, overlapping toxicity is a concern. In this study, investigators aim to study the safety and tolerability of combined avapritinib and decitabine for the treatment of SM-AHN.
This description comes directly from the study's public registry record.
Paul Ciero · 813-745-0774 · Paul.Ciero@moffitt.org
Always discuss trial participation with your own doctor first.
| Mayo Clinic - Arizona | Phoenix, Arizona, United States | Not Yet Recruiting |
| Stanford University Medical Center | Palo Alto, California, United States | Not Yet Recruiting |
| Moffitt Cancer Center | Tampa, Florida, United States | Recruiting |
| Dana-Farber Cancer Institute | Boston, Massachusetts, United States | Not Yet Recruiting |
| University of Michigan | Ann Arbor, Michigan, United States | Not Yet Recruiting |
| Memorial Sloan Kettering Cancer Center | New York, New York, United States | Not Yet Recruiting |
| University of Utah Health | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06327685